Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

HIES and HRC had announced partnering to optimise compressed air system efficiency for HRC’s operations. The reinforced ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to ...

Under the terms of the settlement, Pacira has agreed to provide Fresenius with a license to its patents required to ...

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no ...